Parislondon

PARIS and LONDON - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) (LSE: AZN) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union.

PARIS and LONDON - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (LSE: AZN) today announced that their marketing authorisation application for ONGLYZA(TM) (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.

PARIS and LONDON - Digital Realty Trust Completes Second Turn-Key Datacentre(SM) Lease Agreement with IBM in Paris Digital Realty Trust, Inc.